Understand the source comparison
Best Research Peptides for Intestinal Permeability: Evidence Comparison
BPC-157 Upregulates occludin and ZO-1 via VEGF/FAK pathways 10 mcg/kg daily (animal models) None published for permeability 10–14 days (rodent models) Strongest preclinical evidence for tight junction protein synthesis; reproducible mucosal healing data KPV In
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Upregulates occludin and ZO-1 via VEGF/FAK pathways
- 10 mcg/kg daily (animal models)
- None published for permeability
- 10–14 days (rodent models)
- Strongest preclinical evidence for tight junction protein synthesis; reproducible mucosal healing data
- KPV
- Inhibits NF-κB translocation; blocks cytokine-mediated tight junction degradation
- 5–25 mg/kg oral (animal models)
- 7–10 days inflammatory reduction
- High intestinal accumulation; effective for inflammation-driven barrier damage; poor systemic bioavailability limits off-target effects
- Larazotide acetate
- Zonulin antagonist; prevents tight junction disassembly
- 0.5–2 mg oral 3× daily
- Phase 2b celiac disease trials
- 14–21 days (human data)
- Only peptide with published human permeability data; local action without systemic absorption
- Thymosin Beta-4
- Promotes actin-based cell migration and angiogenesis
- 6–10 mg/kg (animal wound models)
- None for intestinal permeability
- 14–21 days re-epithelialization
- Accelerates tissue repair but lacks specific tight junction data; best for post-inflammatory mucosal restoration